Tissue factor and atherothrombosis

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 6, 2015, Pages 543-549

  Tatsumi, Kohei ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Atherothrombosis; Hyperlipidemia; Microvesicles; Tissue factor

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; THROMBOPLASTIN;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; MEMBRANE MICROPARTICLE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; HUMANS; PLAQUE, ATHEROSCLEROTIC; THROMBOPLASTIN; THROMBOSIS;

EID: 84931064395     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.30940     Document Type: Review

References (70)

1. Mackman N: Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol, 2004; 24: 1015-1022.
2. Tilley R, Mackman N: Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost, 2006; 32: 5-10.
3. Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol, 1989; 134: 1087-1097.
4. Fleck RA, Rao LV, Rapaport SI, Varki N: Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res, 1990; 59: 421-437.
5. Flossel C, Luther T, Muller M, Albrecht S, Kasper M: Immunohistochemical detection of tissue factor TF. on paraffin sections of routinely fixed human tissue. Histochemistry, 1994; 101: 449-453.
6. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmback K, Danton MJ, Colbert MC, Witte DP, Fujikawa K, Davie EW, Degen JL: Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A, 1996; 93: 6258-6263.
7. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D: Role of tissue factor in embryonic blood vessel development. Nature, 1996; 383: 73-75.
8. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr: Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood, 1996; 88: 1583-1587.
9. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr: Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood, 1997; 90: 944-951.
10. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N: Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest, 1998; 101: 560-569.
11. Pawlinski R, Pedersen B, Erlich J, Mackman N: Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost, 2004; 92: 444-450.
12. Pedersen B, Holscher T, Sato Y, Pawlinski R, Mackman N: A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood, 2005; 105: 2777-2782.
13. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A: Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost, 2009; 101: 439-451.
14. Owens AP 3rd, Mackman N: Microparticles in hemostasis and thrombosis. Circ Res, 2011; 108: 1284-1297.
15. Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N, Taubman MB: Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost, 2008; 6: 1983-1985.
16. Tatsumi K, Antoniak S, Monroe DM, 3rd, Khorana AA, Mackman N, Subcommittee on H, Malignancy: Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost, 2014; 12: 1932-1934.
17. Lusis AJ: Atherosclerosis. Nature, 2000; 407: 233-241.
18. Rader DJ, Daugherty A: Translating molecular discoveries into new therapies for atherosclerosis. Nature, 2008; 451: 904-913.
19. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126.
20. Mackman N: Triggers, targets and treatments for thrombosis. Nature, 2008; 451: 914-918.
21. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ: Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol, 2005; 46: 937-954.
22. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C and Stroke Statistics S: Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation, 2014; 129: e28-e292.
23. Minino AM: Death in the United States, 2009. NCHS Data Brief, 2011; 1-8.
24. Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, Peters KG: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation, 1995; 91: 619-622.
25. Ardissino D, Merlini PA, Arlens R, Coppola R, Bramucci E, Lucreziotti S, Repetto A, Fetiveau R, Mannucci PM: Tissue factor in human coronary atherosclerotic plaques. Clin Chim Acta, 2000; 291: 235-240.
26. Borissoff JI, Heeneman S, Kilinc E, Kassak P, Van Oerle R, Winckers K, Govers-Riemslag JW, Hamulyak K, Hackeng TM, Daemen MJ, ten Cate H, Spronk HM: Early atherosclerosis exhibits an enhanced procoagulant state. Circulation, 2010; 122: 821-830.
27. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A: Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis, 1997; 133: 213-219.
28. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB: Identification of active tissue factor in human coronary atheroma. Circulation, 1996; 94: 1226-1232.
29. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT: Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cellmediated thrombogenicity in acute coronary syndromes. Circulation, 1996; 94: 3090-3097.
30. Tremoli E, Camera M, Toschi V, Colli S: Tissue factor in atherosclerosis. Atherosclerosis, 1999; 144: 273-283.
31. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A, 1989; 86: 2839-2843.
32. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM: Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol, 2007; 49: 772-777.
33. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation, 1999; 99: 348-353.
34. Mayr M, Grainger D, Mayr U, Leroyer AS, Leseche G, Sidibe A, Herbin O, Yin X, Gomes A, Madhu B, Griffiths JR, Xu Q, Tedgui A, Boulanger CM: Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet, 2009; 2: 379-388.
35. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L: Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation, 1999; 99: 1780-1787.
36. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT: In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin- labeled factors VIIa and X. Lab Invest, 1996; 75: 451-461.
37. Getz GS, Reardon CA: Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol, 2012; 32: 1104-1115.
38. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, Libby P: Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation, 1999; 100: 1215-1222.
39. Kato K, Elsayed YA, Namoto M, Nakagawa K, Sueishi K: Enhanced expression of tissue factor activity in the atherosclerotic aortas of cholesterol-fed rabbits. Thromb Res, 1996; 82: 335-347.
40. Yamashita A, Matsuda S, Matsumoto T, Moriguchi-Goto S, Takahashi M, Sugita C, Sumi T, Imamura T, Shima M, Kitamura K, Asada Y: Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage- rich neointima but not normal intima of hyperlipidemic rabbits. Atherosclerosis, 2009; 206: 418-426.
41. Jawien J: The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. Curr Pharm Biotechnol, 2012; 13: 2435-2439.
42. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N: Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A, 1992; 89: 4471-4475.
43. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell, 1992; 71: 343-353.
44. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science, 1992; 258: 468-471.
45. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK: Massive xanthomatosis and atherosclerosis in cholesterolfed low density lipoprotein receptor-negative mice. J Clin Invest, 1994; 93: 1885-1893.
46. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME: Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis, 2003; 167: 187-194.
47. Li J, Chen T, Wang D, Song Y, Hong M: Expression and location of intracellular tissue factor in atherosclerosis stable plaque of ApoE -/-. mice. J Huazhong Univ Sci Technolog Med Sci, 2009; 29: 457-461.
48. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation, 2001; 103: 3044-3046.
49. Chi L, Gibson G, Peng YW, Bousley R, Brammer D, Rekhter M, Chen J, Leadley R: Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits. J Thromb Haemost, 2004; 2: 85-92.
50. Yamashita A, Zhao Y, Zhao S, Matsuura Y, Sugita C, Iwakiri T, Okuyama N, Ohe K, Koshimoto C, Kawai K, Tamaki N, Kuge Y, Asada Y: Arterial (18)F-fluorodeoxyglucose uptake reflects balloon catheter-induced thrombus formation and tissue factor expression via nuclear factor- kappaB in rabbit atherosclerotic lesions. Circ J, 2013; 77: 2626-2635.
51. Kuijpers MJ, Gilio K, Reitsma S, Nergiz-Unal R, Prinzen L, Heeneman S, Lutgens E, van Zandvoort MA, Nieswandt B, Egbrink MG, Heemskerk JW: Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J Thromb Haemost, 2009; 7: 152-161.
52. Liu ML, Reilly MP, Casasanto P, McKenzie SE, Williams KJ: Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. Arterioscler Thromb Vasc Biol, 2007; 27: 430-435.
53. Meisel SR, Xu XP, Edgington TS, Cercek B, Ong J, Kaul S, Shah PK: Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocytederived macrophages by oxidized low density lipoprotein. J Atheroscler Thromb, 2011; 18: 596-603.
54. Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N: Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest, 2012; 122: 558-568.
55. Schuff-Werner P, Claus G, Armstrong VW, Kostering H, Seidel D: Enhanced procoagulatory activity PCA. of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis, 1989; 78: 109-112.
56. Ferro D, Basili S, Alessandri C, Cara D, Violi F: Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis, 2000; 149: 111-116.
57. Ferro D, Basili S, Alessandri C, Mantovani B, Cordova C, Violi F: Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet, 1997; 350: 1222.
58. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T: Increased level of oxidized LDL-dependent monocyte- derived microparticles in acute coronary syndrome. Thromb Haemost, 2004; 91: 146-154.
59. Monetti M, Canavesi M, Camera M, Parente R, Paoletti R, Tremoli E, Corsini A, Bellosta S: Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res, 2007; 55: 441-449.
60. Tuomisto TT, Lumivuori H, Kansanen E, Hakkinen SK, Turunen MP, van Thienen JV, Horrevoets AJ, Levonen AL, Yla-Herttuala S: Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res, 2008; 78: 175-184.
61. Owens AP 3rd, Mackman N: The antithrombotic effects of statins. Annu Rev Med, 2014; 65: 433-445.
62. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283.
63. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 2002; 105: 1756-1759.
64. Nagata K, Ishibashi T, Sakamoto T, Ohkawara H, Shindo J, Yokoyama K, Sugimoto K, Sakurada S, Takuwa Y, Nakamura S, Teramoto T, Maruyama Y: Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis, 2002; 163: 39-47.
65. Guha M, Mackman N: The phosphatidylinositol 3-kinase- Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem, 2002; 277: 32124-32132.
66. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol, 1997; 17: 265-272.
67. Muller F, Gailani D, Renne T: Factor XI and XII as antithrombotic targets. Curr Opin Hematol, 2011; 18: 349-355.
68. Kuijpers MJ, van der Meijden PE, Feijge MA, Mattheij NJ, May F, Govers-Riemslag J, Meijers JC, Heemskerk JW, Renne T, Cosemans JM: Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol, 2014; 34: 1674-1680.
69. van Montfoort ML, Kuijpers MJ, Knaup VL, Bhanot S, Monia BP, Roelofs JJ, Heemskerk JW, Meijers JC: Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 2014; 34: 1668-1673.
70. Mackman N: New targets for atherothrombosis. Arterioscler Thromb Vasc Biol, 2014; 34: 1607-1608